A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

Stopped Study was terminated due to poor accrual and associated recrutiment challenges

Conditions

• Sickle Cell Disease
• Vaso-occlusive Crisis
• Vaso-occlusive Pain Episode in Sickle Cell Disease

Interventions

• DRUG: Inclacumab
• DRUG: Placebo

Sponsor

Pfizer